Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin vs Solifenacin vs Mirabegron for Ureteral Stent Symptoms
NCT06803030Phase 3Recruiting
- Sponsor
- Bir Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of tamsulosin, solifenacin, mirabegron in ureteral stent-related symptoms (USRS), sponsored by Bir Hospital. Started Aug 2025; status: recruiting.
02
Drugs
tamsulosinsolifenacinmirabegron
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on NCT06803030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803030.